U.S. Markets closed

BioAtla, Inc. (BCAB)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
47.18+1.36 (+2.97%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close45.82
Open46.58
Bid44.23 x 900
Ask47.66 x 900
Day's Range45.29 - 47.22
52 Week Range27.15 - 49.49
Volume187,584
Avg. Volume428,004
Market Cap1.588B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est49.00
  • BioAtla Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
    PR Newswire

    BioAtla Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

    BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer, today announced the closing of its initial public offering of 12,075,000 shares of common stock at a public offering price of $18.00 per share, which includes 1,575,000 shares sold upon full exercise of the underwriters' option to purchase additional shares of common stock. All of the shares of common stock were offered by BioAtla. The shares of common stock began trading on the Nasdaq Global Market on December 16, 2020 under the ticker symbol "BCAB." The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by BioAtla, were approximately $217.4 million.

  • Barrons.com

    IPO of AI-Lending Firm Upstart Gains 47%

    The gain came after the fintech priced its IPO at the low end of the range it had told investors to expect.

  • Barrons.com

    BioAtla Is the Latest Biotech IPO to Pop

    Shares of the company, which is developing treatments for cancer, closed 72% higher on their first day of trading.